Sarcoidosis is a T-cell driven inflammatory disease characterized by granuloma formation.
their differential expression of CD14 and CD16 as well as CD123 + plasmacytoid DCs (PDCs) and CD1c + and CD141 + myeloid DCs (MDCs) in the respiratory tract. 5, 6 The different subsets of DCs and monocytes have common but also unique features. 7 Classical monocytes circulate in blood and either extravasate into tissues or differentiate into intermediate monocytes and non-classical monocytes. 8 All monocytes can secrete proinflammatory cytokines but classical and intermediate monocytes are the most potent producers, while non-classical monocytes mainly perform immunosurveillance in blood and tissues. 9 Intermediate monocytes are expanded in the circulation of patients with infections, autoimmune, and inflammatory diseases including sarcoidosis. [10] [11] [12] However, respiratory monocytes are less studied and it remains to be elucidated if intermediate monocytes also expand in the lungs of sarcoidosis patients and whether monocytes and DCs contribute to cytokine-mediated granuloma formation similar to AMs. 13 DCs, in particular CD1c + MDCs, potently present antigen to and activate CD4 T cells that drive disease, 14, 15 while CD141 + MDCs are superior at cross-presentation to CD8 T cells. 16, 17 CD123 + PDCs are potent type I interferon producers and the most common DC subset in lymphoid tissue. 18, 19 MNPs from blood and BAL have been studied in sarcoidosis patients with somewhat conflicting results. 20 However, a detailed description comparing anatomical compartments including lung tissue and the lung-draining lymph nodes and distinguishing between clinical phenotypes (LS and non-LS sarcoidosis patients) is lacking. The significance of this strategy was shown in previous studies where the elevated CD4/CD8 T cell ratio in BAL used for diagnosis could not be observed in LLN samples obtained using endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA). 21, 22 Taken together, this underlines the importance of doing comparative studies in different anatomical compartments side-by-side within the same patient to elucidate how the immune response shapes clinical symptoms.
Here, we investigated distribution, phenotype and functional markers of monocytes and DC subsets from BAL, endobronchial biopsies (EBBs), LLNs, and blood within the same sarcoidosis patient in a cohort of LS and non-LS sarcoidosis patients. We found that while monocytes and DCs resided in all compartments investigated, the different cell subsets displayed differential distribution and maturation status including differential chemokine receptor expression. Importantly, cells from BAL samples were not necessarily a reflection of cells obtained from endobronchial tissue or LLNs suggesting heterogeneity in distribution and function in MNPs that can result in different disease outcome in LS and non-LS sarcoidosis patients.
MATERIAL AND METHODS

Study design and patient characteristics
Eleven sarcoidosis patients between the age of 30 and 58 were included in this study. All patients were referred to the University Hospital, Umeå to undergo bronchoscopy. Patients were diagnosed with sarcoidosis as defined by WASOG guidelines 23 based on clinical signs, chest radiography findings, and non-caseating granulomas in the lymph nodes and/or endobronchial biopsy (Table 1) . We identified LS sarcoidosis patients based on the clinical signs (enlarged lymph nodes, erythema nodosum or periarticular arthritis) as well as blood parameters (Table 1) . At time of bronchoscopy, all LS patients still had enlarged lymph nodes, as assessed by computer tomography prior to the bronchoscopy, to conduct EBUS-TBNA. Informed consent was obtained prior to the bronchoscopy. The study was approved by the regional ethical review board in Umeå, Sweden and performed according to the declaration of Helsinki.
Bronchoscopy
Venous blood (32 ml) was drawn from each patient in Vacutainer CPT tubes (BD) before treatment with oral midazolam (4-8 mg) and glycopyrronium (0.2-0.4 mg) i.v. 30 min prior to the bronchoscopy. Lidocaine was administered in larynx and bronchi for topical anesthesia.
A Fujinon bronchoscope (FUJIFILM Corporation, Tokyo, Japan) was inserted through the mouth. First, EBBs were taken from the major carinas of the bronchial tree from one side of the lung. To detect granulomas, EBBs were fixed in paraffin and 4 m-thick sections were stained with hematoxylin and eosin. To avoid blood contamination, BAL with 3 × 60 ml of a saline solution was performed on the contralateral side (middle or lingual lobe). EBUS-TBNA was performed to sample mediastinal and hilar LLNs. LLN aspirates were initially assessed for representability using on-site cytology by transferring LLN aspirates onto glass slides followed by methanol fixation and Diff-Quik stain using Eosin G and Thiazine.
Single cell preparations from blood, respiratory specimens, and lymph nodes
Peripheral blood mononuclear cells (PBMCs) were isolated from blood collected in CPT tubes according to the manufacturer´s protocol. BAL samples were kept on ice, filtered through a 100 m nylon filter (Syntab) and centrifuged at 400 × g for 15 min. EBBs were processed as described earlier. 6 In brief, EBBs were collected in RPMI 1640 with 2% fetal calf serum (FCS). Biopsies were washed in HBSS (SigmaAldrich) for 5 min and incubated with 5 mM 1,4-DTT (Sigma-Aldrich) for 15 min. Incubations were performed on a rocker at 30 rpm at room temperature. Single biopsies were transferred to a 48-well plate and incubated with 0.25 mg/ml Collagenase II and 0.2 mg/ml DNase (both Sigma-Aldrich) in RPMI 1640 for 60 min at 37 • C. After digestion, biopsies were filtered through a 40 m cell strainer (BD). LN aspirates were filtered through a 40 m nylon cell strainer, centrifuged at 300 × g for 10 min. Lysis of red blood cells (RBC) was performed with 1 × RBC lysis buffer (University laboratories, Karolinska Hospital, Solna) for 5 min and subsequently centrifuged at 300 × g for 5 min. Cells were counted manually and Trypan Blue was used to assess viability.
Flow cytometry
Cell suspensions were incubated with LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Life Technologies). Fc receptors were blocked using 
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Statistical analysis
For all experiments, data are shown as median. Data were analyzed using GraphPad Prism version 6.0 (GraphPad Software). To assess statistical significance, non-parametric Kruskal-Wallis with Dunn's test correcting for multiple comparisons and the Mann-Whitney U unpaired t-test were used. Confidence levels lower than P < 0.05 were considered significant.
RESULTS
Consistent numbers of viable cells are obtained from sarcoidosis patient lymph node aspirates after EBUS-TBNA
In this study, 11 patients with sarcoidosis were included of which 4 were clinically characterized with Löfgren's syndrome. All patients underwent bronchoscopy to sample EBBs, BAL and subsequently, the lung-draining mediastinal and hilar lymph nodes using EBUS-TBNA (Fig. 1A ). LLNs were evaluated for granulomas on-site ( 
Mononuclear phagocytes are more frequent in blood than in the lung mucosa and lymph nodes
All samples were processed immediately after collection and stained with a validated panel of antibodies against phenotypic and activation markers to identify and characterize MNPs. We identified live, CD45 + leukocytes in PBMCs, BAL, EBBs, and LLNs using flow cytometry and compared frequencies between the compartments (Supplementary Fig. 1 and Fig. 2A and B) . In BAL samples, AMs were excluded from further analysis based on high autofluorescence to avoid mischaracterization of other MNPs ( Fig. 2A , BAL sample, Supplementary Fig. 1B ).
MNPs were identified among the leukocytes based on their expression of HLA-DR and lack of lineage markers (CD3, CD19, CD20, CD56, and CD66abce) ( (Fig. 2D) . Taken together, our data show that total
MNPs could be identified in all four compartments. However, depending on the sampling site, differences in distribution were observed with highest frequencies of MNPs in blood followed by BAL, EBB, and LLN in all sarcoidosis patients.
Differential distribution of monocyte and DC subsets in blood, lungs, and lymph nodes in sarcoidosis patients
We next characterized six MNP subsets in blood, BAL, EBBs, and LLNs. (Fig. 3A) . In addition, two myeloid DC (MDC) subsets were identified by their expression of CD1c (CD1c + MDC) and CD141 (CD141 + MDC) (Fig. 3A) . We identified three DC and three monocyte subsets in all compartments, with the exception of intermediate and non-classical monocytes that were not detected in EBBs (Fig. 3A) , which is in line with our previous observation in healthy volunteers 6 (Supplementary Table 1 ). Overall, the distribution of monocyte subsets in the different compartments was strikingly different (Fig. 3B) with EBBs containing only classical monocytes and BAL, unlike blood and LLNs, displaying a majority of proinflammatory intermediate monocytes (Fig. 3C) . Three DC subsets were identified in varying frequencies in all the compartments (Fig. 3D ). CD1c + MDCs were the most common subset in blood, BAL, and EBBs while CD123 + PDCs were most abundant in LLNs (Fig. 3E) . Taken together, our data show a higher frequency of DCs in BAL, EBBs, and LLNs than in blood suggesting a recruitment of DCs to the site of inflammation in sarcoidosis patients.
Lack of CD141 + MDCs in EBBs and reduced frequencies of CD123 + PDCs in LLNs of LS compared to non-LS patients
For comparison of total monocytes and DCs, we included data from healthy controls (HC) generated in Baharom et al., 6 an earlier study of our group. The distribution of total monocytes and total DCs (three DC and monocyte subsets, respectively) in blood, BAL, and EBBs was comparable between healthy controls, 6 LS and non-LS patients (Fig. 4A ).
While no data is available on HC in LLNs, non-LS, and LS patients displayed different distribution of monocytes and DCs (Fig. 4A) . Non-LS patients had more DCs than monocytes in LLNs, while LS patients had predominantly monocytes (Fig. 4A) . However, of the individual subsets in LLNs, only CD123 + PDCs were significantly lower in LS patients compared to non-LS patients (Fig. 4B) . Furthermore, no CD141 + MDCs were detected in EBBs of LS patients (Fig. 4B) . Taken together, LLNs displayed the most pronounced difference in MNP distribution comparing LS and non-LS patients.
Monocytes and DCs in sarcoidosis patients are more mature in BAL and EBBs compared to peripheral blood
We next assessed the maturation status of MNPs by analyzing their surface expression of HLA-DR and CD80, which are upregulated upon MNP maturation to facilitate optimal T cell activation. 24 In sarcoidosis, enhanced maturation of MNPs could be an indicator of the . n = 11 for PBMC and BAL while EBBs and LLNs are n = 9. Bars indicate median. Pie charts show the proportion of (C) monocyte and (E) DC subsets in each of the four compartments relative to each other. n.d. = not detectable. Statistical analysis was performed using the non-parametric Kruskal-Wallis with Dunn's test for correction of multiple comparisons. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 inflammatory processes in the different anatomical compartments. We found the most distinct differences in HLA-DR expression on classical monocytes in all compartments; HLA-DR expression was lowest in blood and LLNs, followed by BAL and highest in EBBs (Fig. 5A ).
In contrast, CD80 expression on classical monocytes was highest in cells from BAL followed by EBBs, LLNs, and blood (Fig. 5B) . No differences in HLA-DR and CD80 expression were observed on intermediate monocytes across the tissues (Fig. 5C and D) while non-classical monocytes displayed a similar HLA-DR and CD80 expression to the classical monocytes ( Fig. 5E and F) . Similar to monocytes, all DC subsets in blood and LLNs had comparable levels of HLA-DR while DCs in BAL and EBBs had an increased expression (Fig. 5G-M 
DISCUSSION
Here, we characterized the phenotype and distribution of monocytes MNPs are important in sarcoidosis both in activation and maintenance of pathogenic T cells as well as in contribution to granuloma formation by excessive TNF production by macrophages in the lungs of sarcoidosis patients. 25 However, MNPs have mainly been studied in blood and BAL of sarcoidosis patients and generated heterogeneous data. [26] [27] [28] This could partly be due to clinical heterogeneity among patients and limited differentiation between patients with acute and gradual disease onset. An important novelty of this study is the sideby-side investigation of MNP subsets in blood, BAL, EBBs, and LLNs Table 1 ). Compared to our data generated from healthy volunteers, 6 frequencies of CD1c + MDCs in blood of sarcoidosis patients was decreased ( Supplementary Fig. 1 ). This is in line with previous data from others. 27 Additionally, in EBB of sarcoidosis patients, frequencies of CD1c + MDCs and classical monocytes were increased compared to healthy controls (Supplementary Table 1 ), a finding that we will follow up on in future studies of larger patient cohorts.
The primary reason to perform bronchoscopy and collect EBBs in sarcoidosis patients, was to verify presence of granulomas, which was lower in sarcoidosis patients (median 37%) compared to samples from healthy volunteers (70%), 6 in line with reduced viability after enzymatic digestion when fewer biopsies are processed. 6 However, reduced viability could also reflect an ongoing inflammation resulting in cells that are more sensitive to processing and could cause cell maturation. Indeed, we observed 40% viable CD45 + leukocytes in EBBs of sarcoidosis patients (Fig. 2B ) compared to only 10% CD45 + cells in EBBs from healthy volunteers, 6 in support of inflammation-induced leukocyte infiltration. We have previously reported that LS patients have a higher IL-17, IL-2, and IL-22 production but lower IFN-in BAL T cells compared to non-LS patients. 32 This elevated cytokine production may be linked to the reduced viability we observed in BAL cells from LS patients compared to non-LS patients in the present study (Fig. 1E ).
Sampling LLNs in sarcoidosis patients for analysis of MNPs has not been widely used. Only 1% of LLN cells are MNPs (Fig. 2D) , and to obtain sufficient numbers of cells for analysis, a prerequisite is enlarged LLNs. Generating equivalent EBUS-TBNA data from a suitable non-sarcoidosis control group is challenging since normal-size LLNs would yield too few cells. Instead, we focused on comparing MNPs in LLNs from non-LS versus LS patients. We observed significant differences in the overall distribution of LLN monocytes versus DCs from LS and non-LS patients (Fig. 4A ) suggesting that MNPs directly or indirectly could contribute to disease outcome. The expression of chemokine receptors on MNPs is needed for optimal migration between tissues. A suitable target that could explain different distribution due to migratory behavior could be CCR2 as different haplotypes in LS and non-LS sarcoidosis patients were described. 33, 34 The different distribution of LLN MNPs in LS patients could potentially have impact on granuloma formation since pulmonary monocytes produce higher levels of granuloma-promoting cytokines like TNF than DCs upon activation. 6, 35 Additionally, we found significantly lower frequencies of LLN CD123 + PDCs in LS compared to non-LS patients.
PDCs are potent producers of type I interferons that promote Th1 skewing. IFN-producing Th1 cells in lungs are associated with disease progression in non-LS patients. [36] [37] [38] [39] It remains to be determined if the low frequency of LLN PDCs in LS patients is directly associated with better disease prognosis. Furthermore, the LS patients in this study had no detectable CD141 + MDCs in lung tissue (EBB). CD141 + MDCs specialize in cross-presentation, a process promoted by type I interferons. 40 Whether the comparably low levels of type I IFN producing PDCs in LLNs of LS patients is related to the absence of CD141 + MDCs in lungs of LS and how this translates into T cell responses remains to be understood. To elucidate this, future experiments should focus on analyzing the capability of monocytes and DCs from LS and non-LS patients to produce cytokines and to activate T cells.
Our study cohort included 11 male patients, which does not reflect the overall incidence of newly diagnosed sarcoidosis patients with respect to gender. 41 The uneven gender distribution is likely a consequence of the fact that we were unable to consecutively include all newly diagnosed sarcoidosis patients over the study period, which by chance resulted in a cohort of only male patients. We investigated whether our experimental data correlated with clinical data such as duration, severity of symptoms, lung function or blood chemistry (Table 1) 
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